Actively Recruiting
Impact of Dysbiosis-inducing Drugs on Effectivity of Immune Checkpoint Inhibitor in Non-small Cell Lung Cancer Patients: a Retrospective Study
Led by University Hospital, Strasbourg, France · Updated on 2025-09-24
800
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Lung cancer is a leading cause of death in France, with most patients diagnosed at an advanced metastatic stage. Immunotherapy has improved survival for some metastatic non-small cell lung cancer (NSCLC) patients, but only about 20 to 30% respond to this treatment. Researchers are studying how drugs that alter the gut microbiota before starting immunotherapy may affect patient survival and treatment response in advanced NSCLC cases. The study observes patients with locally advanced (stage III-C) or metastatic (stage IV) NSCLC who receive immunotherapy. It focuses on the impact of medications taken within 90 days before the first immunotherapy dose that might change the gut bacteria composition. This observational study does not involve new treatments but evaluates how these drugs influence progression-free survival. Participants will be followed retrospectively, with researchers collecting data on their treatments, clinical outcomes, and biological markers. The main measure is progression-free survival starting from 90 days before immunotherapy initiation. The study aims to better understand how modifying gut bacteria through certain drugs affects immunotherapy effectiveness and patient survival over time.
CONDITIONS
Brief Title
Impact of Dysbiosis-inducing Drugs on Effectivity of Immune Checkpoint Inhibitor in Non-small Cell Lung Cancer Patients
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adult (≥18 years)
- Confirmed diagnosis of non-small cell lung cancer
- Stage IV or stage III-C non-small cell lung cancer
- Receiving immunotherapy treatment
You will not qualify if you...
- Refusal to reuse data for scientific research purposes
- Minor patient
- Disease stage below stage III-C
- Patient included in a clinical trial with an unknown randomization arm (double-blind study)
- Lack of relevant data on concomitant treatments, biology, or clinical outcomes
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Up to approximately 3 years
Participants who undergo routine care are observed to evaluate the effect of dysbiosis-inducing drugs on immunotherapy outcomes in non-small cell lung cancer.
Trial Site Locations
Total: 1 location
1
Service de Pneumologie - CHU de Strasbourg - France
Strasbourg, France, 67091
Actively Recruiting
Research Team
C
Céline MASCAUX, MD, PhD
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here